Taken together, this study provides convincing evidence that a combinational therapeutic treatment regime that modulates Mcl-1 expression levels may be an efficacious approach to sensitize GBM to the apoptosis-inducing effects of TRAIL. Here, MCL1 is linked to glioblastoma.